HKSE - Delayed Quote HKD
LEE'S PHARM (0950.HK)
1.330
-0.010
(-0.75%)
At close: April 30 at 4:08:15 PM GMT+8
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,399,969
1,399,969
1,053,034
1,233,148
1,266,157
Cost of Revenue
646,614
646,614
501,723
462,393
459,873
Gross Profit
753,355
753,355
551,311
770,755
806,284
Operating Expense
665,703
665,703
558,670
694,226
979,667
Operating Income
87,652
87,652
-7,359
76,529
-173,383
Net Non Operating Interest Income Expense
-12,057
-12,057
-10,364
-5,202
190
Pretax Income
98,113
98,113
30,785
67,861
1,969,366
Tax Provision
29,501
29,501
10,836
22,026
9,482
Net Income Common Stockholders
93,099
93,099
16,698
51,284
1,987,176
Diluted NI Available to Com Stockholders
93,099
93,099
16,698
51,284
1,987,176
Basic EPS
0.16
--
0.03
0.09
3.38
Diluted EPS
0.16
--
0.03
0.09
3.37
Basic Average Shares
588,835
--
588,835
588,835
588,649
Diluted Average Shares
588,835
--
588,836
588,835
589,047
Total Operating Income as Reported
113,142
113,142
43,553
76,560
1,978,583
Total Expenses
1,312,317
1,312,317
1,060,393
1,156,619
1,439,540
Net Income from Continuing & Discontinued Operation
93,099
93,099
16,698
51,284
1,987,176
Normalized Income
111,390.312
111,390.312
12,256.537
84,246.079
-67,248.260
Interest Income
2,133
2,133
1,534
2,393
5,912
Interest Expense
13,823
13,823
11,277
6,619
4,404
Net Interest Income
-12,057
-12,057
-10,364
-5,202
190
EBIT
111,936
111,936
42,062
74,480
1,973,770
EBITDA
259,667
259,667
191,563
226,979
2,120,637
Reconciled Cost of Revenue
646,614
646,614
501,723
462,393
459,873
Reconciled Depreciation
147,731
147,731
149,501
152,499
146,867
Net Income from Continuing Operation Net Minority Interest
93,099
93,099
16,698
51,284
1,987,176
Total Unusual Items Excluding Goodwill
-26,156
-26,156
6,854
-48,802
2,064,748
Total Unusual Items
-26,156
-26,156
6,854
-48,802
2,064,748
Normalized EBITDA
285,823
285,823
184,709
275,781
55,889
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-7,864.688
-7,864.688
2,412.537
-15,839.921
10,323.740
12/31/2021 - 7/15/2002
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade